| Optimizing hydroxychloroquine dosing for patients with COVID‐19: an integrative modeling approach for effective drug repurposing M Garcia‐Cremades, BP Solans, E Hughes, JP Ernest, E Wallender, ... Clinical Pharmacology & Therapeutics 108 (2), 253-263, 2020 | 139 | 2020 |
| Final results regarding the addition of dendritic cell vaccines to neoadjuvant chemotherapy in early HER2-negative breast cancer patients: clinical and translational analysis M Santisteban, BP Solans, L Hato, A Urrizola, LD Mejías, E Salgado, ... Therapeutic Advances in Medical Oncology 13, 17588359211064653, 2021 | 26 | 2021 |
| Moxifloxacin pharmacokinetics, cardiac safety, and dosing for the treatment of rifampicin-resistant tuberculosis in children KK Radtke, AC Hesseling, JL Winckler, HR Draper, BP Solans, S Thee, ... Clinical Infectious Diseases 74 (8), 1372-1381, 2022 | 20 | 2022 |
| Emerging therapeutics, technologies, and drug development strategies to address patient nonadherence and improve tuberculosis treatment M Garcia-Cremades, BP Solans, N Strydom, B Vrijens, GC Pillai, ... Annual review of pharmacology and toxicology 62 (1), 197-210, 2022 | 18 | 2022 |
| Analysis of dynamic efficacy endpoints of the Nix-TB trial BP Solans, MZ Imperial, M Olugbosi, RM Savic Clinical Infectious Diseases 76 (11), 1903-1910, 2023 | 12 | 2023 |
| Population pharmacokinetics of volasertib administered in patients with acute myeloid leukaemia as a single agent or in combination with cytarabine B P. Solans, A Fleury, M Freiwald, H Fritsch, K Haug, IF Trocóniz Clinical Pharmacokinetics 57, 379-392, 2018 | 12 | 2018 |
| Assessing the impact of the addition of dendritic cell vaccination to neoadjuvant chemotherapy in breast cancer patients: A model‐based characterization approach BP Solans, A López‐Díaz de Cerio, A Elizalde, LJ Pina, S Inogés, ... British Journal of Clinical Pharmacology 85 (8), 1670-1683, 2019 | 9 | 2019 |
| Drug exposure to establish pharmacokinetic–response relationships in oncology BP Solans, MJ Garrido, IF Trocóniz Clinical Pharmacokinetics 59 (2), 123-135, 2020 | 8 | 2020 |
| QT interval prolongation with one or more QT-prolonging agents used as part of a multidrug regimen for rifampicin-resistant tuberculosis treatment: findings from two pediatric … AM Ali, KK Radtke, AC Hesseling, J Winckler, HS Schaaf, HR Draper, ... Antimicrobial Agents and Chemotherapy 67 (7), e01448-22, 2023 | 7 | 2023 |
| Influence of NAT2 genotype and maturation on isoniazid exposure in low-birth-weight and preterm infants with or without human immunodeficiency virus (HIV) exposure A Béranger, A Bekker, BP Solans, MF Cotton, M Mirochnick, A Violari, ... Clinical Infectious Diseases 75 (6), 1037-1045, 2022 | 7 | 2022 |
| Neoadjuvant therapy for locally advanced gastric cancer patients. A population pharmacodynamic modeling P Martin-Romano, BP Solans, D Cano, JC Subtil, A Chopitea, L Arbea, ... Plos one 14 (5), e0215970, 2019 | 7 | 2019 |
| Longitudinal model-based biomarker analysis of exposure-response relationships in adults with pulmonary tuberculosis AD Gewitz, BP Solans, WR Mac Kenzie, C Heilig, WC Whitworth, ... Antimicrobial agents and chemotherapy 65 (10), 10.1128/aac. 01794-20, 2021 | 6 | 2021 |
| Modelling of neutrophil dynamics in children receiving busulfan or treosulfan for haematopoietic stem cell transplant conditioning BP Solans, R Chiesa, B Doncheva, H Prunty, P Veys, IF Trocóniz, ... British Journal of Clinical Pharmacology 86 (8), 1537-1549, 2020 | 6 | 2020 |
| Prospective validation and refinement of a population pharmacokinetic model of fludarabine in children and young adults undergoing hematopoietic cell transplantation JT Brooks, BP Solans, Y Lu, S Kharbanda, CC Dvorak, N Lalefar, S Long, ... Pharmaceutics 14 (11), 2462, 2022 | 5 | 2022 |
| Pharmacokinetics and Optimal Dosing of Levofloxacin in Children for Drug-Resistant Tuberculosis: An Individual Patient Data Meta-Analysis YN White, BP Solans, P Denti, LE van der Laan, HS Schaaf, B Vonasek, ... Clinical Infectious Diseases 78 (3), 756-764, 2024 | 4 | 2024 |
| Pharmacokinetics and safety of bedaquiline in HIV-positive and negative older children and adolescents with rifampicin-resistant tuberculosis JA Hughes, BP Solans, HR Draper, HS Schaaf, JL Winckler, ... Clin Infect Dis 75 (10), 1772-1780, 2022 | 4 | 2022 |
| Effectiveness and pharmacokinetic exposures of first-line drugs used to treat drug-susceptible tuberculosis in children: a systematic review and meta-analysis BP Solans, A Béranger, K Radtke, A Mohamed, F Mirzayev, M Gegia, ... Clinical Infectious Diseases 76 (9), 1658-1670fc, 2023 | 3 | 2023 |
| Inpatient pain alleviation after orthopaedic trauma surgery—are we doing a good job? MT Marmor, V Mahadevan, BP Solans, A Floren, L Jarlsberg, I Cohen, ... European Journal of Orthopaedic Surgery & Traumatology 34 (1), 569-576, 2024 | 2 | 2024 |
| Pharmacokinetic analysis across studies to drive knowledge‐integration: A tutorial on individual patient data meta‐analysis (IPDMA) RC van Wijk, MZ Imperial, RM Savic, BP Solans CPT: Pharmacometrics & Systems Pharmacology 12 (9), 1187-1200, 2023 | 2 | 2023 |
| Pharmacokinetics and cardiac safety of clofazimine in children with rifampicin-resistant tuberculosis AM Ali, B P. Solans, AC Hesseling, J Winckler, HS Schaaf, HR Draper, ... Antimicrobial Agents and Chemotherapy 68 (1), e00794-23, 2024 | 1 | 2024 |
